نتائج البحث - "Jeff Isaacson"

المصدر: The Lancet. Oncology, vol 18, iss 1
Swisher, EM; Lin, KK; Oza, AM; Scott, CL; Giordano, H; Sun, J; et al.(2017). Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. The Lancet Oncology, 18(1), 75-87. doi: 10.1016/S1470-2045(16)30559-9. UCLA: Retrieved from: http://www.escholarship.org/uc/item/1gv7r4vjTest

مصطلحات موضوعية: 0301 basic medicine, Oncology, Indoles, endocrine system diseases, HOMOLOGOUS RECOMBINATION DEFICIENCY, Drug Resistance, POLY(ADP-RIBOSE) POLYMERASE, Carcinoma, Ovarian Epithelial, chemistry.chemical_compound, 0302 clinical medicine, Neoplasms, Ovarian Epithelial, Neoplasms, Glandular and Epithelial, Prospective Studies, RANDOMIZED PHASE-2, Peritoneal Neoplasms, Cancer, Ovarian Neoplasms, BRCA1 Protein, OLAPARIB, Glandular and Epithelial, Middle Aged, Prognosis, CANCER, TUMORS, PROSTATE-CANCER, Ovarian Cancer, Survival Rate, Local, 5.1 Pharmaceuticals, 030220 oncology & carcinogenesis, 6.1 Pharmaceuticals, PARP inhibitor, DNA-REPAIR, Female, Development of treatments and therapeutic interventions, Poly(ADP-ribose) Polymerases, Life Sciences & Biomedicine, medicine.medical_specialty, HETEROZYGOSITY, Oncology and Carcinogenesis, BRCA MUTATION, Antineoplastic Agents, Poly(ADP-ribose) Polymerase Inhibitors, BREAST, Olaparib, 03 medical and health sciences, Rare Diseases, Internal medicine, Carcinoma, medicine, Genetics, Fallopian Tube Neoplasms, Humans, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, Rucaparib, REPAIR DEFECTS, Survival rate, Germ-Line Mutation, Aged, Neoplasm Staging, Platinum, Gynecology, BRCA2 Protein, Salvage Therapy, Science & Technology, MUTANT-CELLS, business.industry, BRCA mutation, Evaluation of treatments and therapeutic interventions, International Agencies, medicine.disease, NEGATIVE BREAST-CANCER, 030104 developmental biology, Neoplasm Recurrence, Good Health and Well Being, GENOMIC LOSS, chemistry, Drug Resistance, Neoplasm, Neoplasm, Neoplasm Recurrence, Local, INHIBITORS, business, Ovarian cancer, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bcf5088e366c217c7c8f2dcb4f1cbefTest

9

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial

المؤلفون: David G. Mutch, J I Weberpals, Roberto Sabbatini, D K Armstrong, Susana Banerjee, Domenica Lorusso, Giovanni Scambia, Gottfried E. Konecny, Jonathan A. Ledermann, A Leary, T Neunhöffer, Hani Gabra, J C Goh, G Kichenadasse, R W Holloway, Iris L. Romero, Jesus Garcia-Donas, Martin Buck, Michael Friedlander, Nicoletta Colombo, Robert L. Coleman, Deborah K. Armstrong, Amnon Amit, E M Guerra, Stephen Welch, Salomon M. Stemmer, T Vanderkwaak, C Hänle, Ignace Vergote, Alain Lortholary, Laurence Gladieff, David M. O'Malley, J Garcia-Donas, A Clamp, James Sun, Andrew R Clamp, Mitch Raponi, Laurie Elit, Claudio Zamagni, R T Morris, A Casado Herraez, Y Drew, Benoit You, Thomas Harding, M Vulfovich, L Ma, B M Slomovitz, S Kovel, A Dean, C Aghajanian, Prafull Ghatage, A O'Donnell, L-m Chen, Diane Provencher, G Scambia, D M O'Malley, A El-Balat, Jeffrey C. Goh, M Leviov, Florence Joly, Ronnie Shapira-Frommer, Olivier Tredan, Marie Plante, Stefano Tamberi, Amit M. Oza, Kevin K. Lin, G E Konecny, E M Swisher, A Oaknin, I A McNeish, Johanne I Weberpals, Clare L. Scott, M Amenedo Gancedo, Paul R. Harnett, Mark A. Morgan, A Floquet, Jean-Pierre Lotz, Terri Cameron, Ana Oaknin, Elizabeth M. Swisher, Michael J. Birrer, Setsuko K. Chambers, Peter C.C. Fong, Andrew Dean, Carol Aghajanian, Sandro Pignata, Melanie E Powell, Alessandra Bologna, Caroline Grace, Christine Parkinson, C L Scott, Jeff Isaacson, J. Medioni, Heidi Giordano, Tamar Safra, H Denys, I Palacio, P C Fong, Margarita Amenedo Gancedo, Robert W Holloway, P Krabisch, N Colombo, Mary K. Buss, Alexandra Leary, Pauline Wimberger, A Sanchez, Luc Dirix, Sandra Goble, M Pölcher, Lara Maloney, Anne Floquet, D Jackson, Iain A. McNeish

المساهمون: Coleman, R, Oza, A, Lorusso, D, Aghajanian, C, Oaknin, A, Dean, A, Colombo, N, Weberpals, J, Clamp, A, Scambia, G, Leary, A, Holloway, R, Gancedo, M, Fong, P, Goh, J, O'Malley, D, Armstrong, D, Garcia Donas, J, Swisher, E, Floquet, A, Konecny, G, Mcneish, I, Scott, C, Cameron, T, Maloney, L, Isaacson, J, Goble, S, Grace, C, Harding, T, Raponi, M, Sun, J, Lin, K, Giordano, H, Ledermann, J, Leidos Biomedical Research, Inc.

المصدر: Lancet (London, England), vol 390, iss 10106

مصطلحات موضوعية: 0301 basic medicine, Indoles, Internationality, endocrine system diseases, MULTICENTER, Gene mutation, Medical and Health Sciences, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Molecular Targeted Therapy, 6.2 Cellular and gene therapies, 11 Medical and Health Sciences, Cancer, Ovarian Neoplasms, education.field_of_study, ARIEL3 investigators, Medicine (all), General Medicine, CHEMOTHERAPY, Middle Aged, OPEN-LABEL, SOLID TUMORS, CANCER, Ovarian Cancer, Survival Rate, (ARIEL3), Treatment Outcome, Local, 6.1 Pharmaceuticals, 030220 oncology & carcinogenesis, Female, Life Sciences & Biomedicine, EPITHELIAL OVARIAN, medicine.medical_specialty, ovarian carcinoma, (ARIEL3), Rucaparib, HETEROZYGOSITY, Clinical Trials and Supportive Activities, BEVACIZUMAB, Population, Poly(ADP-ribose) Polymerase Inhibitors, Risk Assessment, Disease-Free Survival, Maintenance Chemotherapy, 03 medical and health sciences, Rare Diseases, Medicine, General & Internal, Double-Blind Method, Clinical Research, General & Internal Medicine, Internal medicine, Genetics, medicine, Humans, education, Rucaparib, Survival rate, Aged, Gynecology, Science & Technology, Performance status, business.industry, BRCA mutation, Evaluation of treatments and therapeutic interventions, ovarian carcinoma, Regimen, Neoplasm Recurrence, Orphan Drug, 030104 developmental biology, Settore MED/40 - GINECOLOGIA E OSTETRICIA, chemistry, Neoplasm Recurrence, Local, business, Recurrent Ovarian Carcinoma, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0275ed6179ab07f49e1cdef255c13c2Test
http://hdl.handle.net/10281/171093Test

10

Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: Translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody

المؤلفون: Thomas Kirchner, Steffen Ormanns, Mitch Raponi, Stefan Boeck, Rüdiger P. Laubender, Volker Heinemann, Jeff Isaacson, Axel Kleespies, Stephan Kruger, Mike Bartosiewicz, Michael Haas, Elaina Mann

المصدر: European Journal of Cancer. 50:1891-1899

مصطلحات موضوعية: Adult, Oncology, Cancer Research, medicine.medical_specialty, Adolescent, Subgroup analysis, Equilibrative nucleoside transporter 1, Deoxycytidine, Drug Administration Schedule, Equilibrative Nucleoside Transporter 1, Capecitabine, Erlotinib Hydrochloride, Young Adult, Predictive Value of Tests, Pancreatic cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Animals, Humans, Prospective Studies, Aged, biology, business.industry, Antibodies, Monoclonal, Cancer, Middle Aged, Prognosis, medicine.disease, Immunohistochemistry, Survival Analysis, Gemcitabine, Pancreatic Neoplasms, Treatment Outcome, Quinazolines, biology.protein, Biomarker (medicine), Fluorouracil, Rabbits, Erlotinib, business, medicine.drug

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685c95d9e5506578fc300d3f0ddf79daTest
https://doi.org/10.1016/j.ejca.2014.04.023Test

تنقيح النتائج